A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to treat children with relapsed AML with CPX-351.
Description
The purpose of this study is to treat children with relapsed AML with CPX-351.
Details
| Condition | Acute Myeloid Leukemia |
|---|---|
| Age | 1years - 21years |
| Clinical Study Identifier | TX7521 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.